[Objectives]To explore the molecular mechanism of Sanzi Yangqin Decoction in the treatment of bronchial asthma based on network pharmacology and molecular docking.[Methods]The components of Fructus Perillae,Semen Raph...[Objectives]To explore the molecular mechanism of Sanzi Yangqin Decoction in the treatment of bronchial asthma based on network pharmacology and molecular docking.[Methods]The components of Fructus Perillae,Semen Raphani and Semen Sinapis three traditional Chinese medicine-related components and targets of Feiduqing Sanzi Yangqin Decoction were obtained using Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP),and the targets of bronchial asthma were obtained using Genecards and OMIM databases.Sanzi Yangqin Decoction"drug-active ingredient-target-disease"network was established with the aid of Cytoscape 3.7.2 software and network topology analysis was carried out.The gene ontology(GO)function enrichment analysis and the KEGG pathway enrichment analysis were performed by DAVID.The top 3 components and targets in the network topology analysis were respectively molecularly docked.[Results]Through network analysis,4 key active components were obtained,mainly luteolin,arachidonic acid,β-carotene,etc.;5 key targets,mainly NCOA2,PGR,PTGS2,etc.Through GO analysis,523 items(P<0.05)were obtained,including 396 items in biological process(BP),53 items in cell composition(CC),and 74 items in molecular function(MF).KEGG analysis generated 144 signal pathways(P<0.05),involving PI3K-Akt signal pathway,human cytomegalovirus infection,Kaposi's sarcoma-associated herpes virus infection,proteoglycans in cancer,prostate cancer,etc.The results of molecular docking showed that core active compounds such as luteolin andβ-carotene in Sanzi Yangqin Decoction had good affinity with NCOA2,PGR,PTGS2 and other target genes,which were similar to clinically recommended chemical drugs.[Conclusions]The active compounds luteolin and carotene in Sanzi Yangqin Decoction may mainly bind to targets such as NCOA2,PGR,PTGS2,and regulate multiple signaling pathways such as PI3K-Akt to play a role in treating bronchial asthma.It is intended to provide new ideas for the clinical application and research of Sanzi Yangqin Decoction.展开更多
目的:系统评价二陈汤合三子养亲汤治疗慢性支气管炎的疗效及安全性。方法:通过计算机检索中国知网、万方、维普、中国生物医学文献数据库、Web of Science、PubMed、Cochrane Library、Embase数据库,收集二陈汤合三子养亲汤治疗慢性支...目的:系统评价二陈汤合三子养亲汤治疗慢性支气管炎的疗效及安全性。方法:通过计算机检索中国知网、万方、维普、中国生物医学文献数据库、Web of Science、PubMed、Cochrane Library、Embase数据库,收集二陈汤合三子养亲汤治疗慢性支气管炎的随机对照试验,检索时间时限从各数据库建库至2023年3月31日,同时检索临床注册试验和灰色文献。对最终纳入的研究采用Cochrance风险偏倚评估工具进行质量评价与偏倚风险评估,并运用RevMan 5.3软件对最终纳入研究进行Meta分析。结果:共纳入13篇RCT文献,共涉及了978例患者,其中治疗组490例,对照组488例。Meta分析结果显示:二陈汤合三子养亲汤干预治疗慢性支气管炎,在临床疗效方面,可以显著提高临床总有效率[OR=3.71,95%CI(2.39,5.75),P<0.00001];在症状、体征方面,可以缩短咳嗽停止时间[MD=-4.73,95%CI(-5.63,-3.83),P<0.00001]、喘息停止时间[MD=-3.78,95%CI(-4.30,-3.27),P<0.00001]、肺部啰音消失时间[MD=-4.15,95%CI(-4.82,-3.73),P<0.00001];在肺功能方面,能改善FEV_(1)[MD=0.33,95%CI(0.25,0.40),P<0.00001],改善FEV_(1)/FCV[MD=16.21,95%CI(1.48,30.94),P=0.03];在炎症因子方面,能降低WBC[MD=-3.02,95%CI(-3.55,-2.50),P<0.00001]、CRP[MD=-15.79,95%CI(-20.53,-11.04),P<0.00001]、TNF-α[MD=-8.96,95%CI(-13.45,-4.46),P<0.00001]。纳入的文献均未报道严重不良反应。结论:二陈汤合三子养亲汤干预治疗慢性支气管炎,可以显著提高临床疗效,缩短患者咳嗽、喘息、肺部啰音消失时间,改善患者的肺功能,降低患者炎症因子水平,安全性有待进一步验证,但是纳入文献的方法质量学总体不高,纳入文献的数量较少,仍需要更多高质量、大样本、多中心的RCT支持。展开更多
基金Science and Technology Planning Project of Lanzhou City(2018-1-117).
文摘[Objectives]To explore the molecular mechanism of Sanzi Yangqin Decoction in the treatment of bronchial asthma based on network pharmacology and molecular docking.[Methods]The components of Fructus Perillae,Semen Raphani and Semen Sinapis three traditional Chinese medicine-related components and targets of Feiduqing Sanzi Yangqin Decoction were obtained using Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP),and the targets of bronchial asthma were obtained using Genecards and OMIM databases.Sanzi Yangqin Decoction"drug-active ingredient-target-disease"network was established with the aid of Cytoscape 3.7.2 software and network topology analysis was carried out.The gene ontology(GO)function enrichment analysis and the KEGG pathway enrichment analysis were performed by DAVID.The top 3 components and targets in the network topology analysis were respectively molecularly docked.[Results]Through network analysis,4 key active components were obtained,mainly luteolin,arachidonic acid,β-carotene,etc.;5 key targets,mainly NCOA2,PGR,PTGS2,etc.Through GO analysis,523 items(P<0.05)were obtained,including 396 items in biological process(BP),53 items in cell composition(CC),and 74 items in molecular function(MF).KEGG analysis generated 144 signal pathways(P<0.05),involving PI3K-Akt signal pathway,human cytomegalovirus infection,Kaposi's sarcoma-associated herpes virus infection,proteoglycans in cancer,prostate cancer,etc.The results of molecular docking showed that core active compounds such as luteolin andβ-carotene in Sanzi Yangqin Decoction had good affinity with NCOA2,PGR,PTGS2 and other target genes,which were similar to clinically recommended chemical drugs.[Conclusions]The active compounds luteolin and carotene in Sanzi Yangqin Decoction may mainly bind to targets such as NCOA2,PGR,PTGS2,and regulate multiple signaling pathways such as PI3K-Akt to play a role in treating bronchial asthma.It is intended to provide new ideas for the clinical application and research of Sanzi Yangqin Decoction.
文摘目的:系统评价二陈汤合三子养亲汤治疗慢性支气管炎的疗效及安全性。方法:通过计算机检索中国知网、万方、维普、中国生物医学文献数据库、Web of Science、PubMed、Cochrane Library、Embase数据库,收集二陈汤合三子养亲汤治疗慢性支气管炎的随机对照试验,检索时间时限从各数据库建库至2023年3月31日,同时检索临床注册试验和灰色文献。对最终纳入的研究采用Cochrance风险偏倚评估工具进行质量评价与偏倚风险评估,并运用RevMan 5.3软件对最终纳入研究进行Meta分析。结果:共纳入13篇RCT文献,共涉及了978例患者,其中治疗组490例,对照组488例。Meta分析结果显示:二陈汤合三子养亲汤干预治疗慢性支气管炎,在临床疗效方面,可以显著提高临床总有效率[OR=3.71,95%CI(2.39,5.75),P<0.00001];在症状、体征方面,可以缩短咳嗽停止时间[MD=-4.73,95%CI(-5.63,-3.83),P<0.00001]、喘息停止时间[MD=-3.78,95%CI(-4.30,-3.27),P<0.00001]、肺部啰音消失时间[MD=-4.15,95%CI(-4.82,-3.73),P<0.00001];在肺功能方面,能改善FEV_(1)[MD=0.33,95%CI(0.25,0.40),P<0.00001],改善FEV_(1)/FCV[MD=16.21,95%CI(1.48,30.94),P=0.03];在炎症因子方面,能降低WBC[MD=-3.02,95%CI(-3.55,-2.50),P<0.00001]、CRP[MD=-15.79,95%CI(-20.53,-11.04),P<0.00001]、TNF-α[MD=-8.96,95%CI(-13.45,-4.46),P<0.00001]。纳入的文献均未报道严重不良反应。结论:二陈汤合三子养亲汤干预治疗慢性支气管炎,可以显著提高临床疗效,缩短患者咳嗽、喘息、肺部啰音消失时间,改善患者的肺功能,降低患者炎症因子水平,安全性有待进一步验证,但是纳入文献的方法质量学总体不高,纳入文献的数量较少,仍需要更多高质量、大样本、多中心的RCT支持。
